EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR TherapyColon cancerEGFR proteinSidednessAnti-EGFR therapyRight- and left-sided colorectal cancers (RSCRC and LSCRC, respectively) are different developmentally, genetically and ...
◆Despite uncertainty over its role as a predictive marker, it is clear that mutations in BRAF are a strong prognostic marker. prospective analysis of tissues from patients with stage II and III colon cancer enrolled i...
近日,《肿瘤学年鉴》(Annals Of Oncology)发表了题为:Different prognostic values ofKRASexon 2 submutations andBRAF V600Emutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDE...
KRAS、BRAF基因突变的结直肠癌患者临床病理特征分析 ㊃论著㊃ ＫＲＡＳ㊁ＢＲＡＦ基因突变的结直肠癌患者临床 病理特征分析 刘威１，王菲２，杜洪３，缪娜波３，李旺林１，２，曹杰１，２∗ （１．广州医科大学附属广州市第一人民医院，广州消化疾病中心，结直肠肛门外科，广东广州５１０１８０；２．广州市第...
Left - KRAS mutant patients, HR = 0.172, p-value < 0.001; right - KRAS wild-type patients, HR = 0.794, p-value = 0.357. Full size image We also assessed the relationship between UHRF1 expression and the expression of previously published lung cancer-specific tumor ...
32/112 261/613 67/181 1.28 (1.09–1.51) 1.05 (0.67–1.64) Abbreviations: CI ¼ confidence interval; CRC ¼ colorectal cancer; HR ¼ hazard ratio; KRAS ¼ Kirsten Ras; MSI ¼ microsatellite instability; MSI-H ¼ high microsatellite instability; mut ¼ mutated; wt ¼ wild-type...
Approximately 30-50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene, indicating that up to 50% of patients with colorectal cancer (CRC) might respond to anti-epidermal growth factor receptor (EGFR) antibody therapy. However, 40-60% of patients with wild-type KRAS tumo...
To validate ERCC1 as a predictor of sensitivity for oxaliplatin, ERCC1 was knocked-down by siRNA in KRAS-wild-type CRC cells, which restored oxaliplatin sensitivity. In contrast, ERCC1 was overexpressed by ERCC1-expressing vectors in KRAS-mutant CRC cells, and caused oxaliplatin resistance. ...
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. Clin Cancer Res 2012; 18: 890-900.Ogino S, Shima K, Meyerhardt JA, et al: Predictive and prognostic roles of ... S Ogino,K Shima,JA Meyerhardt,... - American Associa...